AMZN vs PFE: Which Is the Better Buy?

Side-by-side comparison of Amazon.com, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-04-11.
Amazon.com, Inc. · Consumer Cyclical
$238.12
+59.3% upside to fair value
Grade B High Quality
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction Grade B+
QuantHub Verdict
AMZN has more upside to fair value (+59.3%). PFE trades at a lower forward P/E (9.5x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric AMZN PFE
Current Price $238.12 $26.91
Fair Value Estimate $379.40 $35.00
Upside to Fair Value +59.3% +30.1%
Market Cap $2,556.2B $153.0B
Forward P/E 32.8x 9.5x
EV / EBITDA 15.9x 13.8x
Price / Sales 3.6x 2.4x
Price / FCF 332.2x 16.8x
Revenue Growth YoY +18.4% -1.6%
Gross Margin 50.3% 70.3%
Operating Margin 11.2% 24.7%
Return on Equity 21.9% 9.0%
Dividend Yield 0% 6.4%
FCF Yield 0.3% 5.9%
Analyst Consensus Strong Buy Hold
Investment Thesis
AMZN — Amazon.com, Inc.
Amazon.com, Inc. operates as the world's largest e-commerce and cloud computing company, with a diversified revenue base spanning online retail, third-party seller services, AWS cloud, advertising, and subscription services. The business quality is high due to its durable competitive moats including AWS's leadership in cloud infrastructure and Amazon's dominant e-commerce platform. Despite strong…
PFE — Pfizer Inc.
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
Metric AMZN PFE
Zone Low $284.55 $25.00
Zone High $322.49 $29.00
In Buy Zone? Yes Yes
← AMZN Research    PFE Research →    All Research